Bristol Myers 거래 BMY

매도
 매수

BristolMyers 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

BristolMyers news

Magnificent 7 earnings, US and Japan inflation due next week
Neil Wilson 2024 Jul 18, 16:00

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Forex Indices
Wall Street earnings
Neil Wilson 2023 Oct 20, 10:00

Week ahead: Earnings bonanza, ECB decision & US inflation

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

2022 Jul 24, 05:42

Week ahead: Fed to hike 100bps into a recession?

최신 뉴스

더 보기
Noah Lee 2025 Sep 12, 10:20

US-Japan Joint Statement: Reaffirming Market-Driven Exchange Rates

Emma Rose 2025 Sep 12, 09:20

Goldman Sachs, UBS Raise Gold Price Forecasts for 2025

Noah Lee 2025 Sep 12, 09:20

Albania Appoints AI Minister to Combat Corruption in Public Procurement

Emma Rose 2025 Sep 11, 15:20

Dalio: Gold as a Hedge Against Mounting Debt Risks

Ava Grace 2025 Sep 11, 14:20

Switzerland Proposes US Gold Refinery to Reduce Tariffs

Noah Lee 2025 Sep 11, 14:20

NATO and EU on Edge After Russian Drone Enters Poland: A Critical Test

Liam James 2025 Sep 11, 10:20

Economists Anticipate BOJ Rate Hike in Q4 Amidst Global Uncertainties

Sophia Claire 2025 Sep 11, 10:20

Fed Rate Cut Debate Intensifies: Employment Data Revision Fuels Calls for Action

정보

스프레드

0.29

스프레드(%)

0.6119 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

금요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

96764821504

발행 주식 수

2035440000

수익 날짜 (다음)

2001-08-07

배당수익률

2025-08-01

배당락일

2025-07-03

예상 연간 배당금

2.48

예상 연간 배당수익률

0.0526

EPS

2.49

이 상품에 대해 자세히 알아보기

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments

latest_education_articles

더 보기
Trustpilot